21 September 2023 - Jazz Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Enrylaze (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia and lymphoblastic lymphoma in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli derived asparaginase.

Enrylaze, approved as Rylaze in the United States and Canada, is a new Erwinia derived asparaginase developed using a next-generation recombinant technology with a safety profile consistent with that of other asparaginase preparations.

Read Jazz Pharmaceuticals press release